Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | IL6ST | P40189 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 8/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049820 | 1.00 | NAAA (0.46) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL1049822 | 1.00 | NAAA (0.46) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL5670354 | 0.90 | PPARA (0.46) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL5670355 | 0.90 | PPARA (0.46) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL4205626 | 0.89 | PPARA (0.44) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL17241987 | 0.89 | IDH1 (0.45) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL7066044 | 0.89 | PPARA (0.44) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL17241988 | 0.89 | IDH1 (0.45) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL8883087 | 0.89 | IDH1 (0.45) | NAAAIL6STPPARAIDH1FAAH | |
| SCHEMBL4205621 | 0.89 | PPARA (0.44) | NAAAIL6STPPARAIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576500-A2 | PROCESS FOR PRODUCING ALISKIREN | Chemo Iberica, S.A. (ES) | 2013-04-10 | — | — | EP | claimed |
| WO-2011151442-A2 | PROCESS FOR PRODUCING ALISKIREN | CHEMO IBERICA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| WO-2025045233-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| US-20230312589-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230024521-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-115003300-A | JAK inhibitors | 维玛兰生物科学公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-4034107-A1 | JAK INHIBITORS | Vimalan Biosciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114269734-A | JAK inhibitors | 维玛兰生物科学公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3966209-A1 | JAK INHIBITORS | Vimalan Biosciences, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5606078-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545750-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0678514-A1 | 3,5-Disubstituted tetrahydrofuran-2-ones | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5254697-A | Process for the preparation of haloalkyllactones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136329-B2 | JAK inhibitors | JAK1, JAK2, JAK3 | NAAA 4608/4885IL6ST 105/4885PPARA 2534/4885 |
| US-20230312589-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | NAAA 3379/4885IL6ST 153/4885PPARA 1363/4885 |
| US-20230024521-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | NAAA 3379/4885IL6ST 153/4885PPARA 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.